Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Secretin in Functional Dyspepsia and Healthy Subjects
NCT03617861Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Nov 2018
- Primary completion
- Jul 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of secretin in functional dyspepsia (FD) (4 arms), sponsored by Mayo Clinic. Primary endpoints: Maximum Satiation at 60 minutes, Fasting Gastric Volume and 4 more. Started Nov 2018; status: completed.
02
Drugs
secretin
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on NCT03617861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617861.